| Short facts | |
| API | BI1029539 |
| Technology | - |
| Indication | Microvascular disease |
| Development phase | Finalized phase 1, will enter phase 2 in Q4 2020 |
| Expected filing with FDA | - |
| In-house or partnership | Partnership with Gesynta Pharma AB |
Unmet need
Several severe microvascular complications currently have few or no approved pharmacological treatment options.
The aim
Gesynta Pharma, who owns all the rights to OX-MPI (GS-248), aims to develop a treatment for the microvascular diseases in chronic inflammatory conditions.
Differentiation
More effective and/or safer than currently approved treatments.